利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1998 条记录 (耗时 0.04 秒)

    Treatment of prostate cancer
    61.
    发明授权
    Treatment of prostate cancer 有权

    公开(公告)号：US11583526B2

    公开(公告)日：2023-02-21

    申请号：US16998900

    申请日：2020-08-20

    申请人： Myovant Sciences GmbH ,  Takeda Pharmaceutical Company Limited

    发明人： Vijaykumar Reddy Rajasekhar ,  Brendan Mark Johnson ,  David B. MacLean ,  Lynn Seely ,  Paul N. Mudd, Jr.

    IPC分类号： A61K31/517 ,  A61K31/4164 ,  A61P35/00 ,  A61K31/501 ,  A61K31/513 ,  A61K9/00 ,  A61K31/4166

    摘要： Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

    METHOD FOR PRODUCING T CELLS
    65.
    发明申请
    METHOD FOR PRODUCING T CELLS 有权

    公开(公告)号：US20220411752A1

    公开(公告)日：2022-12-29

    申请号：US17773467

    申请日：2020-10-30

    申请人： Kyoto University ,  Takeda Pharmaceutical Company Limited

    发明人： Shin KANEKO ,  Hisashi YANO ,  Tokuyuki SHINOHARA

    IPC分类号： C12N5/0783 ,  C12N15/90

    摘要： Provided is an excellent method for producing an IL-4 non-secreting and IFN-γ secreting (Th1-type) or IFN-γ non-secreting and IL-4 secreting (Th2-type) CD4 single-positive T cell (CD4SP T cell). The method for producing the Th1-type or Th2-type CD4SP T cell of the present invention comprises a step of inducing a CD4 single-positive T cell from a hematopoietic stem cell (HSC) and/or a hematopoietic progenitor cell (HPC) substantially defective in a factor involved in IL-4 secretion or a factor involved in IFN-γ secretion.

    TREATMENT OF PROSTATE CANCER
    68.
    发明申请
    TREATMENT OF PROSTATE CANCER 有权

    公开(公告)号：US20220401443A1

    公开(公告)日：2022-12-22

    申请号：US17866203

    申请日：2022-07-15

    申请人： Myovant Sciences GmbH ,  Takeda Pharmaceutical Company Limited

    发明人： Vijaykumar Reddy RAJASEKHAR ,  Brendan Mark JOHNSON ,  David B. MACLEAN ,  Lynn SEELY ,  Paul N. MUDD, JR.

    IPC分类号： A61K31/501 ,  A61P35/00 ,  A61K31/513 ,  A61K9/00 ,  A61K31/4166

    摘要： Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.